Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like peptide 1 infusion increases liver glucose uptake in the conscious dog

Diabetes

Volumn 58, Issue 1, 2009, Pages 243-249

  Edgerton, Dale S ^a   Johnson, Kathryn M S ^a   Neal, Doss W ^a   Scott, Melanie ^a   Hobbs, Charles H ^b   Zhang, Xia ^c   Duttaroy, Alokesh ^c   Cherrington, Alan D ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; VILDAGLIPTIN; ADAMANTANE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG DERIVATIVE; GLUCAGON; NITRILE; PYRROLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONSCIOUSNESS; CONTROLLED STUDY; DOG; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; GLUCOSE METABOLISM; NONHUMAN; PORTAL VEIN; PRIORITY JOURNAL; ANIMAL; DRUG ANTAGONISM; LIVER; METABOLISM;

ADAMANTANE; ANIMALS; ANTIGENS, CD26; CONSCIOUSNESS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOGS; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; INSULIN; LIVER; NITRILES; PYRROLIDINES;

EID: 63249101127     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db08-0515     Document Type: Article

References (49)

1. Drucker DJ: The biology of incretin hormones. Cell Metab 3:153-165, 2006
2. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830, 2002
3. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ: Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126-1131, 1995
4. Vilsboll T, Agerso H, Krarup T, Holst JJ: Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88:220-224, 2003
5. Ahren B, Gomis R, Standl E, Mills D, Schweizer A: Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin- treated patients with type 2 diabetes. Diabetes Care 27:2874-2880, 2004
6. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A: Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89:2078-2084, 2004
7. Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA: The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 92:1249-1255, 2007
8. Edgerton DS, Cardin S, Emshwiller M, Neal D, Chandramouli V, Schumann WC, Landau BR, Rossetti L, Cherrington AD: Small increases in insulin inhibit hepatic glucose production solely caused by an effect on glycogen metabolism. Diabetes 50:1872-1882, 2001
9. Edgerton DS, Neal DW, Scott M, Bowen L, Wilson W, Hobbs CH, Leach C, Sivakumaran S, Strack TR, Cherrington AD: Inhalation of insulin (Exu- bera) is associated with augmented disposal of portally infused glucose in dogs. Diabetes 54:1164-1170, 2005
10. Donmoyer CM, Chen SS, Hande SA, Lacy DB, Ejiofor J, McGuinness OP: Hyperinsulinemia compensates for infection-induced impairment in net hepatic glucose uptake during TPN. Am J Physiol Endocrinol Metab 279:E235-E243, 2000
11. Galassetti P, Koyama Y, Coker RH, Lacy DB, Cherrington AD, Wasserman DH: Role of a negative arterial-portal venous glucose gradient in the postexercise state. Am J Physiol 277:E1038-E1045, 1999
12. Moore MC, Hsieh PS, Neal DW, Cherrington AD: Nonhepatic response to portal glucose delivery in conscious dogs. Am JPhysiol Endocrinol Metab 279:E1271-E1277, 2000
13. Meier JJ, Nauck MA: The potential role of glucagon-like peptide 1 in diabetes. Curr Opin Investig Drugs 5:402-410, 2004 14. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE: Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 90:4888-4894, 2005
14. Ionut V, Hucking K, Liberty IF, Bergman RN: Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones. Diabetologia 48:967-975, 2005
15. Johnson KM, Edgerton DS, Rodewald T, Scott M, Farmer B, Neal D, Cherrington AD: Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels. Am J Physiol Endocrinol Metab 293:E1085-E1091, 2007
16. Ahren B, Holst JJ, Martensson H, Balkan B: Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol 404:239-245, 2000
17. Drucker DJ: Enhancing incretin action for the treatment oftype 2 diabetes. Diabetes Care 26:2929-2940, 2003
18. Ahren B, Thomaseth K, Pacini G: Reduced insulin clearance contributes to the increased insulin levels after administration of glucagon-like peptide 1 in mice. Diabetologia 48:2140-2146, 2005
19. Groop PH, Groop L, Totterman KJ, Fyhrquist F: Relationship between changes in GIP concentrations and changes in insulin and C-peptide concentrations after guar gum therapy. Scand J Clin Lab Invest 46:505-510, 1986
20. Kindmark H, Pigon J, Efendic S: Glucose-dependent insulinotropic hormone potentiates the hypoglycemic effect of glibenclamide in healthy volunteers: evidence for an effect on insulin extraction. J Clin Endocrinol Metab 86:2015-2019, 2001
21. Rudovich NN, Rochlitz HJ, Pfeiffer AF: Reduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant first-degree relatives of type 2 diabetic patients. Diabetes 53:2359-2365, 2004
22. Brandt A, Katschinski M, Arnold R, Polonsky KS, Goke B, Byrne MM: GLP-1-induced alterations in the glucose-stimulated insulin secretory dose- response curve. Am J Physiol Endocrinol Metab 281:E242-E247, 2001
23. Hanks JB, Andersen DK, Wise JE, Putnam WS, Meyers WC, Jones RS: The hepatic extraction of gastric inhibitory polypeptide and insulin. Endocrinology 115:1011-1018, 1984
24. Meier JJ, Gallwitz B, Siepmann N, Holst JJ, Deacon CF, Schmidt WE, Nauck MA: The reduction in hepatic insulin clearance after oral glucose is not mediated by gastric inhibitory polypeptide (GIP). Regul Pept 113:95-100, 2003
25. Meier JJ, Holst JJ, Schmidt WE, Nauck MA: Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans. Am J Physiol Endocrinol Metab 293:E849-E856, 2007
26. Ionut V, Liberty IF, Hucking K, Lottati M, Stefanovski D, Zheng D, Bergman RN: Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action. Am J Physiol Endocrinol Metab 291:E779-E785, 2006
27. Kawai K, Suzuki S, Ohashi S, Mukai H, Ohmori H, Murayama Y, Yamashita K: Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases. Endocrinology 124:1768-1773, 1989
28. van der Burg MP, Guicherit OR, Frolich M, Gooszen HG: Insulinotropic effects of cholecystokinin, gastric inhibitory polypeptide and glucagon-like peptide-1 during perifusion of short-term cultured canine isolated islets. Regul Pept 60:61-67, 1995
29. Edgerton DS, Stettler KM, Rodewald TD, Farmer B, Lautz M, Hastings J, Snead W, Scott M, Cherrington AD: Intraportal exendin delivery increases liver and muscle glucose utilization (Abstract). Diabetes 55:A28, 2006
30. Ionut V, Zheng D, Stefanovski D, Bergman RN: Exenatide can reduce glucose independent of islet hormones or gastric emptying. Am J Physiol Endocrinol Metab 295:E269-E277, 2008
31. Johnson KM, Edgerton DS, Rodewald T, Scott M, Farmer B, Neal D, Cherrington AD: Intraportally delivered GLP-1, in the presence of hypergly- cemia induced via peripheral glucose infusion, does not change whole body glucose utilization. Am J Physiol Endocrinol Metab 294:E380-E384, 2008
32. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hufner M, Schmiegel WH: Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 87:1239-1246, 2002
33. Ahren B, Larsson H, Holst JJ: Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:473-478, 1997
34. Orskov L, Holst JJ, Moller J, Orskov C, Moller N, Alberti KG, Schmitz O: GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabeto- logia 39:1227-1232, 1996
35. Ryan AS, Egan JM, Habener JF, Elahi D: Insulinotropic hormone glucagon- like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab 83: 2399-2404, 1998
36. Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA: Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia 45:1410-1415, 2002
37. Prigeon RL, Quddusi S, Paty B, D'Alessio DA: Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancre- atic effect. Am J Physiol Endocrinol Metab 285:E701-E707, 2003
38. Dardevet D, Moore MC, DiCostanzo CA, Farmer B, Neal DW, Snead W, Lautz M, Cherrington AD: Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors. Am, J Physiol Gastrointest Liver Physiol 289:G806-G814, 2005
39. Dardevet D, Moore MC, Neal D, DiCostanzo CA, Snead W, Cherrington AD: Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region. Am JPhysiol Endocrinol Metab 287:E75-E81, 2004
40. Vella A, Shah P, Basu R, Basu A, Camilleri M, Schwenk FW, Holst JJ, Rizza RA: Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes. Diabetes 50:565-572, 2001
41. Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Gingerich R, Egan JM, Elahi D: Glucagon-like peptide-1 (7-37) augments insulin-mediated glucose uptake in elderly patients with diabetes. J Gerontol A Biol Sci Med Sci 56:M681-M685, 2001
42. Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Gingerich R, Egan JM, Finegood DT, Elahi D: Effect of glucagon-like peptide 1 on non-insulin- mediated glucose uptake in the elderly patient with diabetes. Diabetes Care 24:1951-1956, 2001
43. Egan JM, Montrose-Rafizadeh C, Wang Y, Bernier M, Roth J: Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metab- olism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. Endocrinology 135:2070-2075, 1994
44. Cervera A, Wajcberg E, Sriwijitkamol A, Fernandez M, Zuo P, Triplitt C, Musi N, DeFronzo RA, Cersosimo E: Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 294:E846-E852, 2008
45. Myers SR, McGuinness OP, Neal DW, Cherrington AD: Intraportal glucose delivery alters the relationship between net hepatic glucose uptake and the insulin concentration. J Clin Invest 87:930-939, 1991
46. Vahl TP, Tauchi M, Durler TS, Elfers EE, Fernandes TM, Bitner RD, Ellis KS, Woods SC, Seeley RJ, Herman JP, D'Alessio DA: Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 148:4965-4973, 2007
47. Villanueva-Penacarrillo ML, Delgado E, Trapote MA, Alcantara A, Clem- ente F, Luque MA, Perea A, Valverde I: Glucagon-like peptide-1 binding to rat hepatic membranes. J Endocrinol 146:183-189, 1995
48. Wheeler MB, Lu M, Dillon JS, Leng XH, Chen C, Boyd AE III: Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C. Endocrinology 133: 57-62, 1993
49. Valverde I, Morales M, Clemente F, Lopez-Delgado MI, Delgado E, Perea A, Villanueva-Penacarrillo ML: Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Lett 349:313-316, 1994